Home › Acute Kidney Injury › NCT07222722

NIRS Monitoring in the NICU and AKI

Near Infrared Spectroscopy (NIRS) Monitoring as an Early Predictor of Acute Kidney Injury (AKI) in a Vulnerable Neonatal Intensive Care Unit (NICU) Population

Who can join

24 Weeks – 30 Weeks · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Any neonate less than 30 weeks in gestational age
* Willingness and capacity of both adult parents/guardians to sign consent

Exclusion Criteria:

* An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)
* Age \>30 weeks gestational age
* Age \<24 weeks and \<500 grams (will be excluded due to sensitivity of skin in this vulnerable population).
* Clinician's decision that NIRS is not suitable due to the patient's clinical condition

About the study

The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \<30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \<30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.

What is being tested

• NIRS Monitoring (device)

Sponsor: NYU Langone Health · Participants: 100 · Started: 2025-11

Contact the study team

• Jordan Nelson, MD · Phone: 3478223664

Official record on ClinicalTrials.gov — NCT07222722

Locations in the U.S.

Conditions

• Acute Kidney Injury

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.